[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vaccine-acceptance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vaccine-acceptance":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100643606","addressing-hpv-vaccine-hesitancy-by-co-designing-a-digital-health-intervention-100643606",false,"NCT07632963","Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention","HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden","HPV-END-IT","We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.\n\nAll Year 5 pupils and their caregivers in the study schools are invited.\n\nInclusion Criteria:\n\n* The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period\n* The school is located in an area with HPV vaccine uptake \\\u003C85.2% (the Stockholm regional average)\n* The head principal and school nurse both consent to participate\n* The school has the capacity to implement the intervention\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",true,"ALL",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.\n\nResearchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.\n\nAfter using the platform, participants will be asked to share their thoughts.",[27,28,29,30],"HPV","Vaccine Acceptance","Vaccine Decision Making","HPV Vaccination",[32,33,34,35],"Human papilloma virus","HPV vaccine","Vaccine uptake","Vaccine confidence","NOT_YET_RECRUITING","2026-06-02",{"date":39,"type":40},"2026-06-08","ACTUAL",{"date":42,"type":21},"2026-08",{"date":44,"type":21},"2027-06",{"name":46,"class":47},"Karolinska Institutet","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100598966","phase-1-clinical-trial-phase-iiia-to-evaluate-the-safety-and-immunogenicity-of-streptincor-100598966","NCT07078357","Clinical Trial Phase I\u002FIIa to Evaluate the Safety and Immunogenicity of StreptInCor","Phase I\u002FIIa Clinical Trial to Evaluate the Safety and Immunogenicity of StreptInCor, a Synthetic Vaccine Against Streptococcus Pyogenes, in Healthy Adult Volunteers.","StreptInCorVac","Inclusion Criteria:\n\n* • Healthy male or female volunteers, aged between 18 and 45 years;\n\n  * Availability to undergo all procedures throughout the study period;\n  * Provide free and informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Participation in clinical trials within the last year\n* Participation in cohort studies\n* Diagnosis of concomitant infections or diseases that may affect immunity, including active HIV infection, hepatitis B, hepatitis C, diabetes mellitus, neoplasms, and autoimmune diseases;\n* Current or previous diagnosis or family history of ARF, chorea, obsessive-compulsive disorder, or glomerulonephritis;\n* Current or previous diagnosis of heart diseases;\n* Severe asthma or chronic obstructive pulmonary disease (COPD);\n* Abnormal neurological clinical assessment, especially chorea;\n* Use of treatments that may affect immunity in the last four weeks, including immunomodulators, corticosteroids (only systemic use for two weeks or more), or antineoplastic agents;\n* Use of treatments that may affect heart valves in the last four weeks or planned during the study period, including fenfluramine and dexfenfluramine;\n* Renal insufficiency determined by estimated creatinine clearance below 45 ml\u002Fmin\u002F1.73m²;\n* History of intolerance or allergy to any component of the study product, including antigen or adjuvant;\n* Presence of valve abnormalities or alterations in cardiac anatomy as defined by echocardiogram;\n* Altered electrocardiogram;\n* Evidence or suspicion of recent S. pyogenes infection based on clinical symptoms in the last four weeks;\n* Pregnancy, breastfeeding mother, or intention to become pregnant during the study period (only female participants);\n* Any other condition that may interfere with the study process as assessed by the researchers, including sample size and statistical power.","18 Years","45 Years",{"count":59,"type":21},60,[61,62],"PHASE1","PHASE2","This is a Phase I\u002FIIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor. The study will include four different doses (25 µg, 50 µg, 100 µg, and 200 µg) of StreptInCor produced under Good Manufacturing Practices (GMP) and formulated with aluminum hydroxide as the vaccine adjuvant. The adjuvant alone will be used as a placebo in this trial. Five groups, each consisting of twelve healthy adult volunteers, will randomly receive two doses of the vaccine or placebo with a 28-day interval, along with a booster dose six months after the initial vaccination",[65,66,67,68,28,69],"Rheumatic Heart Disease","Rheumatic Heart Disease in Children","Vaccine Adverse Reaction","Rheumatic Diseases","Vaccine",[71,72,73,74,75],"Acute rheumatic fever","Rheumatic heart disease","Vaccine development program","Group A streptococcus (GAS)","Streptococcus pyogenes","2025-07-17",{"date":78,"type":40},"2025-07-22",{"date":80,"type":21},"2025-10-01",{"date":82,"type":21},"2028-12-01",{"name":84,"class":47},"University of Sao Paulo General Hospital",1]